CANCER OF THE BLOOD AND BLOOD-FORMING SYSTEMS
Reliable statistics on death rates among chronic leukemia patients are difficult to find. Orthodoxy speaks in terms of a "median survival" of only three years, and admits that the effects of currently accepted therapy have not been adequately evaluated?
The use of one of the chemotherapy drugs of choice, Leukeraz, carries with it the risk of irreversible damage to the bone marrow. Another chemotherapy drug, Cytoxan, has produced cancer in rats and mice. Some of the reactions Cytoxan has produced in humans include: nausea, vomiting, bleeding and inflammation of the colon, severe bleeding from the bladder, and in males, possible irreversible loss of sperm production. The use of metabolic therapy does not involve these kinds of risks. These facts should be kept in mind while reading the following case histories.
Laetrile Case Histories
R106B: Chronic Lymphatic Leukemia
On July 3, 1973, this sixty-two-year-old man went to his local doctor because he had developed a lump on his neck. One week later, this was biopsied, and because of the findings he was referred to a blood and cancer specialist in Sacramento, California. The consulting physicianís summary dated August 6, 1973, reads in part:
In this case, I note left axillary and left in-guinal adenopathy and also the scar from the biopsy of a node in the right supraclavicular area.
It was my feeling that he also had an en-larged spleen.
We obtained on July 27, 1973, a hemoglobin of 15 gin., with a 47% hematocrit. The white count was 24,000 [lab normals, 5,000-10,000), due to an 84% mature lymphocytosis. The platelet count was 211,000 and the reticulocyte count was
uric acid 6.3 mg.%; creatinine 1.1 mg.%.
I obtained a bone marrow biopsy which in-dicated approximately 60% infiltration of the bone marrow by mature lymphocytes.
Mr. R. states that a few days after hit lump was diagnosed as chronic lymphatic leukemia a friend approached him and his wife with information about Laetrile. He stated he will be "eternally grateful" for the information. On July 23, 1973, he began metabolic therapy including Laetrile.
In a letter to the Richardson Clinic dated February 20, 1976, he summarized his reaction to the diagnosis and the suggested treatments.
This sixty-five-year-old gentleman and his wife were interviewed at length in November, 1975, two years and four months following the initiation of metabolic therapy. The patientís eyes sparkled like a young manís, and his skin was clear and fight. He had a handsome gray beard that would have been a pho-tographerís delight. His mannerism was animated.
He stated that, before beginning metabolic therapy including Laetrile, and adopting a vegetarian diet, his mind was confused and his disposition "not that good." He stated he feels much better now and concluded:
He and his wife of many years turned their gray heads toward one another and smiled tenderly. He took her hand in his and looked up at me and said, "Thanks to Dr. Richardson, Iím a whole man now."
Mr. R. continues to lead an active life three and one-half years following the diagnosis of leukemia. With the exception of three days of chemotherapy he has had no treatment other than metabolic therapy including Laetrile.
The parents of the patient were not satisfied with their childís progress because she continued to grow weak. They took her first to Dr. Contreras in Mexico and later to the Richardson Clinic where she began metabolic therapy including Laetrile on January 22, 1975. Her alkaline phosphatase was 134 mu/ml at that time (laboratory normal 30-85 mu/ml). White blood count was low (4,900 cu.mm) due to previous chemo-therapy.
Miss C. has continued on her maintenance program of diet and vitamins. She has returned to school and en-joys horseback riding.
In a letter dated July 20, 1976 (one and one-half years after the patient began metabolic therapy), the following statement was made by the patientís phy-sician in New Jersey:
W130B: Chronic Myelogenous Leukemia
This thirty-nine-year-old woman was found to have a white blood count of 73,000 during a routine physical examination in January, 1973. Subsequent bone marrow studies referred to three different labora-tories all confirmed the diagnosis of leukemia.
Further studies at the Virginia Mason Clinic in Seattle, Washington, reconfirmed the diagnosis. She was placed on Myleran and Zylorprim, after having had their possible adverse side effects explained to her.
Mrs. W. continued to follow the recommendations of the Virginia Mason Clinic until July, 1975, at which time she came to the Richardson Clinic for meta-bolic therapy including Laetrile. Her white blood count has continued to stay within normal limits as of this writing, and the patient stated she feels "so much bet-ter" than before beginning metabolic therapy. It is, of course, possible that this is a natural remission and that at some future time her white blood count might again climb. However, the patient has already been spared ten months of palliative treatment with Myle-ran, an alkylating agent whose possible toxic side ef-fects include: skin hyperpigmentation (changes in skin color), irreversible pulmonary fibrosis (formation of scar tissue in the connective tissue framework of the lungs leaving the patient permanently unable to breathe properly), and renal damage (kidney dam-age).
AIO2SM Chronic Lymphatic Leukemia
This sixty-two-year-old male, Doctor of Chiro-practic, first developed symptoms of extreme weakness and night sweats in October, 1972. Prior to that he had had a gradual weight loss of twenty-five pounds.
In December, 1972, he went to his local M.D. Subsequent laboratory exams showed an elevated WBC (white blood count) of 350,000 and a depressed RBC (red blood count) of 4.0 gins. The diagnosis of chronic lymphatic leukemia was made. Chest X-rays were negative for mediastinal node and lung involve-ment. By January 16, 1973, his WBC had risen to 710,000, seventy-one times normal.
His initial contact with the Richardson Clinic was February 1, 1973. The patientís chief complaint was extreme fatigue. He was jaundiced and his liver and spleen were enlarged. The patient began metabolic therapy on his first visit.
During the course of the next six months, his strength increased and he was able to resume most of his chiropractic duties. The jaundice gradually de-creased and the liver and spleen could no longer be felt. The liver was still moderately tender in July, 1973, however.
In addition to the metabolic therapy regimen, the patient was on Prednesone every other day as a con-trol for his hemolytic (destruction of red blood cells) tendency. The patientís WBC continued to be elevated, around 200,000 per cu. mm., but he manifested none of the other symptoms usually associated with chronic lymphatic leukemia, which are: enlarged liver and spleen, extreme weakness, jaundice, and hemorrhage.
In February, 1974, this patient decided to dis-continue his Laetrile therapy. By May 14, 1974, his WBC had risen to 815,000 per cu.mm. (eighty-one times normal) and his hemoglobin (RBC) had dropped to 5.0 gin. His spleen and liver could be felt again. He became jaundiced and was bothered by ankle ede-ma.
He returned to his metabolic therapy program, and his June 14, 1974, hematology (blood study) report revealed WBC 595,000 per cu.mm. and hemoglobin 8.9gm.
This patient continues to have a WBC which is considerably above normal (lab high normal, 10,000), averaging around 200,000. As of this writing, how-ever, the patientówho, three years ago, was too weak to workóis able to carry on his daily routine as if he did not have leukemia, provided he stays on his diet and medication.
F121G: Chronic Lymphatic Leukemia, Coronary Artery Disease, and Bronchitis
Mr. F. first began to have difficulty with enlarged axillary (under arm) lymph nodes in January, 1974. According to the patient, his local doctor was not par-ticularly concerned despite repeated complaints.
In October of 1974, Mr. F. sought another physicianís opinion and was subsequently admitted to a hospital in Livermore, California, for diagnostic studies. These confirmed the diagnoses of leukemia.
The patient states the diagnosis made him quite depressed because he had watched his daughter die slowly from cancer. The memories of her last days and the morphine injections made him determined not to have any radiation or chemotherapy.
About this time, another daughter of his had been reading about Laetrile and metabolic therapy and suggested that her father try it.
The patient began metabolic therapy in Novem-ber of 1974. The lymph nodes gradually decreased in size. Mr. F. stated that he began to feel better and no longer had pain shortly after beginning treatment. He gained weight and stated that, in his opinion, even the heart pain was less of a problem.
Following the initial course of therapy, he re-turned to his local doctor for a routine check-up. Upon the doctorís advice, he was X-rayed again, and the X-rays were negative for regional lymphadenopathy (en-larged lymph nodes) indicating the cancer was under control.
The patient stated he intends to remain on a main-tenance dose of B17 because, in his opinion, it not only has extended his life but has saved him from the tortures-turn of orthodox chemotherapy.
As of our last contact with this patient, the symptoms of his cancer had been absent for one and one-half years. The only treatment he has received is meta-bolic therapy including Laetrile.